title: N-acetyl cysteine versus allopurinol in the prevention of contrast nephropathy in patients with chronic kidney disease: A randomized controlled trial.
abstract: Contrast media administration can lead to acute deterioration in renal function particularly in patients with pre-existing chronic kidney disease. This prospective, randomized controlled open-label parallel group study was undertaken at Nizam's Institute of Medical Sciences, Hyderabad, from June to December 2015. A total of 95 patients were included, of which 35 received n-acetylcysteine (NAC) + normal saline (NS), 30 patients received allopurinol (ALL) + NS, and 30 patients received placebo. In our study, the overall incidence of CIN was 24%. Incidence of CIN in NAC + NS, ALL + NS, and placebo group were 20%, 16%, and 36%, respectively. The major finding of this study was there was no significant difference between NAC and allopurinol in the prevention of contrast nephropathy. However, only allopurinol was superior to placebo. In our study, hyperuricemia and baseline serum creatinine were the only risk factors associated with CIN.
authors.affiliation: Department of Nephrology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India.
authors.forename: R
authors.initials: R
authors.lastname: Sadineni
authors.affiliation: Department of Nephrology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India.
authors.forename: K R
authors.initials: KR
authors.lastname: Karthik
authors.affiliation: Department of Nephrology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India.
authors.forename: G
authors.initials: G
authors.lastname: Swarnalatha
authors.affiliation: Department of Nephrology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India.
authors.forename: U
authors.initials: U
authors.lastname: Das
authors.affiliation: Department of Nephrology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India.
authors.forename: G
authors.initials: G
authors.lastname: Taduri
keywords: Allopurinol; N-acetylcysteine; chronic kidney disease; contrast nephropathy